Anti-IL-17A Monoclonal Antibody

IL17-A (also known as Interleukin-17) is a proinflammatory cytokine produced by activated T cells. This cytokine regulates the activities of NF-kappaB and mitogen-activated protein kinases. This cytokine can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO) . High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. IL17-A is the founding member of a group of cytokines called the IL17 family. IL17-A was originally identified as a transcript from a rodent T-cell hybridoma. To elicit its functions, IL17 binds to a type I cell surface receptor called IL17R of which there are at least three variants IL17RA, IL17RB, and IL17RC. Anti-IL-17A antibody is ideal for investigators involved in Immunology research.

Anti-IL-17A (MOUSE) Monoclonal Antibody was produced in mouse by repeated immunizations with mature full length recombinant human IL-17A produced in E.coli followed by hybridoma development.

Anti-Human IL-17A (MOUSE) Monoclonal Antibody was purified from concentrated tissue culture supernate by Protein G chromatography followed by extensive dialysis against the buffer stated above. This antibody is specific for human IL-17A protein. A BLAST analysis was used to suggest cross-reactivity with IL-17A from human sources based on 100% homology with the immunizing sequence. Cross-reactivity with IL-17A from other sources has not been determined.

Store vial at -20°C prior to opening. Aliquot contents and freeze at -20°C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4°C as an undiluted liquid. Dilute only prior to immediate use. Expiration date is one (1) year from date of opening.

Anti-Human IL-17A antibody has been tested for use in Western Blot and suitable in FLOW. Specific conditions for reactivity should be optimized by the end user.